SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CASTELLAZZI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.375
AS - Asia 7.099
EU - Europa 3.799
SA - Sud America 1.046
AF - Africa 167
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 14
Totale 24.528
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.141
SG - Singapore 2.752
CN - Cina 1.791
BR - Brasile 819
VN - Vietnam 786
IT - Italia 678
HK - Hong Kong 587
DE - Germania 543
UA - Ucraina 540
PL - Polonia 475
GB - Regno Unito 413
TR - Turchia 385
FI - Finlandia 300
FR - Francia 211
JP - Giappone 183
SE - Svezia 165
RU - Federazione Russa 153
IN - India 134
CA - Canada 115
MX - Messico 94
ID - Indonesia 86
BD - Bangladesh 80
AR - Argentina 79
ZA - Sudafrica 68
AT - Austria 66
IQ - Iraq 63
NL - Olanda 57
CZ - Repubblica Ceca 40
CO - Colombia 36
BE - Belgio 33
PK - Pakistan 33
ES - Italia 30
UZ - Uzbekistan 27
VE - Venezuela 26
AU - Australia 25
EC - Ecuador 25
IR - Iran 23
MA - Marocco 21
SA - Arabia Saudita 21
PY - Paraguay 20
PH - Filippine 18
EG - Egitto 17
LT - Lituania 17
CL - Cile 16
KR - Corea 14
AE - Emirati Arabi Uniti 13
KE - Kenya 13
IE - Irlanda 12
NP - Nepal 12
ET - Etiopia 10
KZ - Kazakistan 10
MY - Malesia 10
UY - Uruguay 10
DZ - Algeria 9
JO - Giordania 9
PE - Perù 9
A2 - ???statistics.table.value.countryCode.A2??? 8
AZ - Azerbaigian 8
IL - Israele 8
PT - Portogallo 8
TN - Tunisia 8
AL - Albania 7
RO - Romania 7
EU - Europa 6
HR - Croazia 6
LB - Libano 6
AO - Angola 5
BG - Bulgaria 5
BO - Bolivia 5
TH - Thailandia 5
BH - Bahrain 4
BY - Bielorussia 4
HN - Honduras 4
JM - Giamaica 4
KG - Kirghizistan 4
PS - Palestinian Territory 4
TW - Taiwan 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HU - Ungheria 3
LV - Lettonia 3
LY - Libia 3
MN - Mongolia 3
NZ - Nuova Zelanda 3
OM - Oman 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
CH - Svizzera 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
LK - Sri Lanka 2
MD - Moldavia 2
NG - Nigeria 2
Totale 24.504
Salva come PNG Salva come JPEG
Città #
Singapore 1.686
Ashburn 1.577
Woodbridge 1.121
Fairfield 905
San Jose 831
Chandler 714
Houston 597
Beijing 592
Hong Kong 580
Jacksonville 562
Santa Clara 527
Warsaw 459
Ann Arbor 391
Seattle 330
Wilmington 328
Cambridge 294
Ho Chi Minh City 258
Dallas 245
New York 233
Los Angeles 231
Ferrara 228
Izmir 223
Nanjing 187
Hanoi 180
Tokyo 178
Princeton 153
Milan 134
Lauterbourg 132
Munich 132
Helsinki 120
Boardman 108
Council Bluffs 103
Shanghai 95
San Diego 87
São Paulo 86
Dearborn 77
Orem 72
The Dalles 70
Addison 65
Buffalo 63
Jakarta 60
London 60
Mexico City 58
Turku 57
Nanchang 55
Tianjin 53
Vienna 51
Brooklyn 49
Montreal 49
Shenyang 48
Bremen 47
Chennai 47
Changsha 42
Hebei 42
Jiaxing 42
Chicago 40
Denver 38
Norwalk 37
Phoenix 37
Stockholm 36
Atlanta 34
Hefei 34
Johannesburg 34
Brussels 33
Frankfurt am Main 33
Haiphong 33
Poplar 31
Baghdad 30
Toronto 30
Brno 29
Falls Church 26
Moscow 26
Bologna 24
Boston 24
Da Nang 24
Manchester 24
Tashkent 24
San Francisco 23
Guangzhou 22
Redwood City 22
Amsterdam 21
Nuremberg 21
San Mateo 21
Zhengzhou 21
Dong Ket 20
Jinan 20
Ningbo 20
Rio de Janeiro 20
Auburn Hills 19
Biên Hòa 19
Orange 19
Belo Horizonte 18
Brasília 18
Mountain View 17
Ankara 16
Washington 16
Columbus 15
Falkenstein 15
Kunming 15
Shenzhen 15
Totale 16.828
Salva come PNG Salva come JPEG
Nome #
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment 412
Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals 289
A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis 282
Decreased Arylesterase activity of Paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases 279
Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara 262
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker 249
Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage 247
Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients 245
Epstein-Barr virus and Multiple Sclerosis: in-depth analysis of the virus-specific antibody response at the time of diagnosis and during therapy 245
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 238
Comparison of antibodies with amylase activity from cerebrospinal fluid and serum of patients with multiple sclerosis 236
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 235
Chlamydia pneumoniaespecific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms 234
Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules 233
Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment 232
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 224
Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis 223
Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders 222
Emerging topics and new perspectives on HLA-G 218
Epidemiological health and social study on multiple sclerosis in the Ferrara province 216
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 214
Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies 213
A Further Evidence Of Pathogenic Role Of Chlamydia Pneumoniae In Multiple Sclerosis 212
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis 211
A proteomic approach to detect gelatinases levels and their inhibitors in patients with neurological diseases 210
A new developed culture method efficiently supports the growth of Chamydia pneumoniae in PBMC and CSF samples from patients with Multiple Sclerosis 207
Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients 205
Affinity distribution of anti-EBV IgG in the cerebrospinal fluid of patients with multiple sclerosis and in controls 203
Cerebrospinal fluid analysis and the determination of oligoclonal bands 200
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS 200
An overview on the relationship between Epstein-Barr virus and multiple sclerosis 198
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis 198
25-hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis 195
Matrix metalloproteinase 9 as a marker of disease activity in multiple sclerosis 193
Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients 192
Clinical and MRI activity are associated to elevated cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-9 in multiple sclerosis patients 186
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy 186
Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis 186
DNA Sequences of Parachlamydia-like organisms in CSF of Patients with Neurological Disorders 181
Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient 181
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES Identification of a TIMP-1-resistant active MMP-9 in serum of Multiple Sclerosis patients 180
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding 178
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 178
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings 176
Altered miRNA expression in T regulatory cells in course of multipla sclerosis 175
Effect of pH on MMP-9 release by LPS-stimulated neutrophils 174
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 are elevated in in multiple sclerosis patients with disease activity 174
Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. 174
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR THE IMPLEMENTATION A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES IN MS. 172
Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms 172
Altered miRNA expression in T regulatory cells in course of multiple sclerosis 172
25 hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis during relapse and remission 171
Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients 171
Analysis of MMP-9 in CSF and sera of patients with neurological diseases 169
Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis 165
CSF levels and soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis 165
Elevated CSF and serum levels and intrathecal synthesis of active MMP-2 in MS patients with no evidence of MRI disease activity 162
Timing of Serum Soluble HLA-G Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage 162
Intrathecal levels of vitamin D and IgG in multiple sclerosis 160
Detection of Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response in a subset of patients with progressive forms of multiple sclerosis 160
Biomolecular and immunological diagnostic aspects of toxoplasmosis during AIDS. 160
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS - ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES. 159
Neurofilament ELISA validation 158
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 157
Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseases-affected patients 157
Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study 153
Effect of HLA-G gene polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. 149
EBV-specific intrathecal oligoclonal antibody response in multiple sclerosis patients 149
Decrease Paraoxonase-1 (PON-1) Activities in Neurodegenerative Diseases 149
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis 148
Cerebrospinal fluid oligoclonal free light chain profiles in AIDS 146
Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study 145
Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients 145
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms 143
Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies 143
INTRATHECAL PRODUCTION OF ACTIVE FORM OF MATRIX METALLOPROTEINASES-9 IN PATIENTS WITH MULTIPLE SCLEROSIS: PRELIMINARY RESULTS” 141
Cerebrospinal fluid free Kappa and Lambda lights chains in MS. A qualitative analysis 141
CSF levels of soluble classical HLA-I and non-classical HLA-G molecules in relapsing-remitting multiple sclerosis and their association with CSF IL-10 concentrations and MRI findings. 141
Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity 141
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 140
Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study 138
Aspetti diagnostici biomolecolari ed immunologici della toxoplasmosi in pazienti AIDS. 138
Chlamydia pneumonia-specific CFS-restricted oligoclonal IgG bands are associated to a subset of patients with prosessive forms of multiple sclerosis. 136
Cerebrospinal Fluid Analysis in Rheumatological Diseases with Neuropsychiatric Complications and Manifestations: A Narrative Review 135
SERUM GELATINASES LEVELS IN MULTIPLE SCLEROSIS PATIENTS DURING 21 MONTHS OF NATALIZUMAB TREATMENT 135
Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology 135
The Diagnostic Utility of Oligoclonal Bands in Multiple Sclerosis: A Time-Course Analysis 134
N-acetylaspartate, glutammate and aspartate levels in multiple sclerosis cerebrospinal fluid. 133
Inflammation and axonal damage biomarkers in Multiple Sclerosis: new perspective on their role 132
Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients 132
Low prevalence of antibodies against Simian Virus 40 in serum samples from patients affected by neurologic diseases, including multiple sclerosis 131
Gelatinase: enzymatic activity as potential biomarker in multiple sclerosis 131
Ruolo dei micro RNA nel funzionamento delle cellule T immunoregolatorie CD4 e CD25 nell'ambito della Sclerosi Multipla 130
Intrathecal synthesis of interleukin-12 in multiple sclerosis 127
MMP-9 isoforms in serum of Multiple Sclerosis patients 127
Gelatinases: enzymatic activity as potential biomarker in multiple sclerosis 126
Extracellular pH modulates the release of Matrix Metalloproteinase-9 (MMP-9) by stimulated neutrophils and its activity. 126
Sex Differences in Albumin Quotient and Cerebrospinal Fluid Total Protein Content Do Not Depend on Anthropometric Factors 124
Inverse association between CSF levels of solubile HLA-G and Fas molecules in MS patients with no evidence of MRI disease activity. 124
Neuroimmune interaction that operate in the development and progression of inflammatory demyelinating diseases: lessons from pathogenesis of multiple sclerosis 124
Totale 17.985
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.147
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.087
Totale 106.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021618 0 0 0 0 0 0 0 0 0 271 241 106
2021/20221.327 34 162 74 57 44 60 60 65 53 122 95 501
2022/20231.599 154 138 35 236 252 230 117 152 166 6 73 40
2023/2024956 79 88 45 25 101 187 27 85 35 25 28 231
2024/20253.531 76 79 275 142 447 302 117 159 679 385 494 376
2025/20269.615 999 379 835 1.331 1.489 715 1.331 573 970 993 0 0
Totale 24.811